Mineralys FY2022 net loss $29.8M; cash $110.1M plus $202M IPO; lorundrostat pivotal trials H1 2023

Mineralys Therapeutics, Inc.

Net loss for FY2022 was $29.8M vs $19.4M in FY2021, driven by higher R&D and G&A costs.
Cash and marketable securities were $110.1M at Dec 31, 2022; Feb 2023 IPO raised net ~$202M.
Positive Phase 2 Target-HTN data presented; FDA end-of-Phase 2 meeting completed.
Pivotal ADVANCE-HTN Phase 2 trial planned H1 2023; Phase 3 trial planned H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mineralys Therapeutics, Inc. reported the full-year ended December 31, 2022 results: net income $29.8 million.

Period: the full-year ended December 31, 2022
Net income: $29.8 million
Result: reported results

Exact text from the filing

Net loss was $29.8 million for the full year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-23-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.